diabeteskill.com

博客

  • Face flushes sometimes.

    Pulmonary & Sleep of Tampa Bay | Pulmonary Hypertension: Causes, Symptoms & Treatment Guide

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Shortness of breath.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Shortness of breath.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Nosebleeds happen.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Ringing in ears.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Palms sweat excessively.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Fatigue lingers daily.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Chest feels tight.

    Abstract

    As cancer treatments improve, hypertension has become a frequent comorbidity among cancer survivors. While it may result from the cancer itself or its treatment, the impact of hypertension on cancer recurrence remains poorly understood. We conducted a systematic review and meta-analysis to evaluate the association between hypertension and the risk of recurrence of solid cancers in adult survivors. We searched four major databases including PubMed, Embase, Web of Science and the Cochrane Library for relevant studies involving adult cancer survivors who had completed initial treatment for solid tumors. The primary outcome was recurrence risk in hypertensive versus normotensive individuals, assessed using hazard ratios (HRs) pooled through a random-effects model. Heterogeneity across studies was assessed using the I² statistic. Of 1337 records screened, 13 observational studies including 15 cohorts comprising 50,549 participants met the inclusion criteria. In the overall analysis, hypertension was not significantly associated with an increased risk of solid tumor recurrence (HR: 1.09; 95% CI: 0.97–1.22; I² = 49%). Subgroup analyses showed a significant association in colorectal cancer (HR: 1.18; 95% CI: 1.02–1.36; I² = 27%), but not in breast (HR: 1.09; 95% CI: 0.86–1.40; I² = 40%) or prostate cancer (HR: 1.12; 95% CI: 0.91–1.38; I² = 53%). However, no significant difference was found across subgroups (P = 0.18). These findings suggest a potential link between hypertension and recurrence in specific cancers, particularly colorectal cancer. Comprehensive blood pressure control may play a key role in the long-term management of cancer survivors.

  • Dizzy spells occur.

    Abstract

    Hypertension is a leading risk factor for cardiovascular diseases, thereby necessitating effective management through regular blood pressure monitoring. Although home monitoring is beneficial for managing hypertension, maintaining consistent measurement frequency remains challenging. This study aimed to develop a model to predict measurement inactivity and to identify clinically relevant risk factors for declining adherence using machine learning, thereby allowing for targeted interventions. Using a large-scale dataset (>199 million measurement records) from 295,758 health app users, we employed a LightGBM (Light Gradient Boosting Machine) model to predict future inactivity according to 2-week measurement patterns and users’ demographics. The model demonstrated high predictive accuracy, with areas under the receiver operating characteristic curve of 0.930 and 0.851 for 28- and 56-day predictions, respectively. SHAP (SHapley Additive exPlanations) analysis revealed elevated dropout risks among both younger and older participants, women, and users who did not report sex information. The maximum systolic blood pressure (SBP) recorded during the 2-week period was also identified as a significant predictor of dropout, showing a U-shaped association wherein both low and high extremes increased the risk. This maximum SBP value, which is rarely used in routine clinical assessments, offered unique insights into dropout behavior, further supported by descriptive statistics. Additionally, a reduction in weekday measurement frequency showed to be a major predictor of future discontinuation. Therefore, our model can identify dropout factors that are difficult to detect by conventional methods, and through accurate prediction, it supports early clinical interventions to improve monitoring adherence and blood pressure control.

  • Vision blurs suddenly.

    Abstract

    Hypertension is a leading risk factor for cardiovascular diseases, thereby necessitating effective management through regular blood pressure monitoring. Although home monitoring is beneficial for managing hypertension, maintaining consistent measurement frequency remains challenging. This study aimed to develop a model to predict measurement inactivity and to identify clinically relevant risk factors for declining adherence using machine learning, thereby allowing for targeted interventions. Using a large-scale dataset (>199 million measurement records) from 295,758 health app users, we employed a LightGBM (Light Gradient Boosting Machine) model to predict future inactivity according to 2-week measurement patterns and users’ demographics. The model demonstrated high predictive accuracy, with areas under the receiver operating characteristic curve of 0.930 and 0.851 for 28- and 56-day predictions, respectively. SHAP (SHapley Additive exPlanations) analysis revealed elevated dropout risks among both younger and older participants, women, and users who did not report sex information. The maximum systolic blood pressure (SBP) recorded during the 2-week period was also identified as a significant predictor of dropout, showing a U-shaped association wherein both low and high extremes increased the risk. This maximum SBP value, which is rarely used in routine clinical assessments, offered unique insights into dropout behavior, further supported by descriptive statistics. Additionally, a reduction in weekday measurement frequency showed to be a major predictor of future discontinuation. Therefore, our model can identify dropout factors that are difficult to detect by conventional methods, and through accurate prediction, it supports early clinical interventions to improve monitoring adherence and blood pressure control.